Recent Updates
Recently added Catalysts

MEDI-528 /kg

Phase 1

Healthy | Monoclonal antibody | Other |AstraZeneca PLC|Last Updated: Dec 11, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
CONTROLLEDBiomarker
Total Trials1
Total Enrollment29
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00116168Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528PHASE1 COMPLETED 29Jun 1, 2005Jul 1, 2006Dec 11, 20132 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Incidence of Adverse Events
Days 0 - 84

Number of participants experiencing adverse events (includes both adverse events and serious adverse events)

Incidence of Abnormal Troponin Levels
Days 0, 1, 7, 14, and 28

Number of participants with troponin levels greater than upper limit of normal

Incidence of Clinically Significant Changes From Baseline in Neurologic Exam
Days 0, 7, 14, 21, 28, 42, and 84

Number of participants with clinically significant changes from baseline in neurologic exam

Incidence of Changes From Baseline in the Day 28 Magnetic Resonance Imaging (MRI) of the Brain
Days 0 and 28

Number of participants with changes from baseline in the Day 28 MRI of the brain

Incidence of Serious Adverse Events
Days 0 - 84

Number of participants experiencing serious adverse events

Secondary Endpoints
Incidence of Anti-drug Antibodies (ADA) to MEDI-528
Days 0, 14, 28, 42, and 84
Time to Observed Maximum Serum Concentration (Tmax)
Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84
Observed Maximum Serum Concentration (Cmax)
Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
MEDI-528 0.3 mg/kgEXPERIMENTALMEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
MEDI-528 1 mg/kgEXPERIMENTALMEDI-528 (1 mg/kg) administered as a single, SC dose
MEDI-528 3 mg/kgEXPERIMENTALMEDI-528 (3 mg/kg) administered as a single, SC dose
MEDI-528 9 mg/kgEXPERIMENTALMEDI-528 (9 mg/kg) administered as a single, SC dose
Interventions
NameTypeDescription
MEDI-528 0.3 mg/kgBIOLOGICALMEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
MEDI-528 1 mg/kgBIOLOGICALMEDI-528 (1 mg/kg) administered as a single, SC dose
MEDI-528 3 mg/kgBIOLOGICALMEDI-528 (3 mg/kg) administered as a single, SC dose
MEDI-528 9 mg/kgBIOLOGICALMEDI-528 (9 mg/kg) administered as a single, SC dose
Unlock Study Design Details
Eligibility Criteria
Age Range19 Years — 49 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: * Males and females age 19 up to, and including, 49 years of age at the time of the first dose of study drug * Weight less than 89 kg * Written informed consent obtained from the volunteer * Healthy by medical history and physical examination * Sexually active females, unless su...

Countries:United States
Unlock Eligibility Criteria